Empagliflozin Treatment is Associated with Improved Beta Cell Function in T2DM.

Empagliflozin Treatment is Associated with Improved Beta Cell Function in T2DM.

J Clin Endocrinol Metab. 2018 Jan 12;:

Authors: Al Jobori H, Daniele G, Adams J, Cersosimo E, Solis-Herrera C, Triplitt C, DeFronzo RA, Abdul-Ghani M

Abstract
Objective: To examine whether lowering the plasma glucose concentration with empagliflozin (SGLT2 inhibitor) improves beta cell function in T2DM.
Research Design and Methods: 15 T2DM patients received empagliflozin (25 mg/day) for 2 weeks, and beta cell function was measured with 9-step hyperglycemic clamp (each step = +40 mg/dl) before and 48 hours and 14 days after empagliflozin.
Results: Empagliflozin caused 101±10 and 117±11 grams glucosuria on days 1 and 14 and produced 25±6 and 38±8 mg/dl reduction (p<0.05 for both) in fasting plasma glucose, respectively. Empagliflozin increased the incremental area under the plasma C-peptide concentration curve by 48±12% and 61±10% during the stepped hyperglycemic clamp performed 48 hours and 14 days, respectively (both p <0.01), after the start of empagliflozin. Empagliflozin also caused an increase in the glucose infusion rate during the hyperglycemic clamp performed on days 3 and 14 compared to baseline by 15% and 16% (both p<0.05), respectively. Beta cell function, measured as the insulin secretion/insulin resistance (IS/IR) index, increased by 73±21% and 112±20% (both p<0.01) 48 hours and 14 days after the start of empagliflozin. Empagliflozin also enhanced beta cell glucose sensitivity during the hyperglycemic clamp by 42% and 54% after 48 hours and 14 days, respectively (both p< 0.01).
Conclusion: Lowering the plasma glucose concentration with empagliflozin in T2DM patients: (1) augments beta cell glucose sensitivity and (2) improves beta cell function (IS/IR index).

PMID: 29342295 [PubMed - as supplied by publisher]

http://ift.tt/2mR6Km5